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The utility of array comparative genomic hybridization (CGH)
testing in prenatal diagnosis has been recently described1,2 with
potential advantages, including improved detection of
pathogenic chromosomal rearrangements following rapid
analysis of uncultured chorionic villi or amniocytes. Whilst some
of the technical difﬁculties encountered in the prenatal setting,
such as DNA extraction for rapid results and interpretation of
calls, have already been discussed, others, such as conﬁned
placental mosaicism (CPM) are yet to be evaluated.
Conﬁned placental mosaicism for aneuploidies, and whole
chromosome arm rearrangements, is a well-established
phenomenon in chorionic villus samples (CVS), with a
reported incidence of 1–2%.3 However, so far as we are aware,
CPM for submicroscopic changes found by microarray testing
has not been previously reported. Here, we report a case of
CPM involving a deletion of exons 7–10 of the STS gene
detected following analysis of array CGH results obtained from
uncultured chorionic villi. The mosaic deletion was conﬁrmed
by an independent method [Multiplex Ligation-dependent
Probe Ampliﬁcation (MLPA)]. The STS deletion was not
subsequently detected by analysis of cultured chorionic villus
cells (CVS-CC) or neonatal blood obtained after delivery at
term, conﬁrming CPM.
Chorionic villus sampling was performed following
sonographic detection at 12-week gestation of an increased
nuchal translucency of 4.2mm, absent nasal bone, ﬁxed ﬂexed
knees and abnormal lower extremities. The CVS was carefully
prepared by microscopic dissection, and the villi were then
ﬁnely macerated and mixed. The macerated villi were used to
establish cell cultures for karyotyping and to extract DNA for
quantitative ﬂuorescent polymerase chain reaction (QF-PCR)
aneuploidy testing (glass bead extraction method4 and
in-house developed QF-PCR method5 as described previously)
and for microarray analysis [extraction using the QIAcube
instrument (Qiagen, Germany)]. Parental blood samples were
also obtained, and DNA was extracted using the FLEX STAR
instrument (AutoGen, USA). After completion of karyotyping,
cells were further cultured, and DNA was extracted using the
iGENatal extraction kit (iGEN, Spain) and stored. Neonatal
blood was obtained, and DNA was extracted using the
QIAsymphony instrument (QIAGEN, Germany). Microarray
testing was performed on DNA from direct CVS, CVS-CC,
neonatal blood, maternal blood and paternal blood. All
microarray testing was performed using sex-matched control
DNA and the NimbleGen CGH 12× 135K WGT v3.0 whole
genome array platform at a resolution of approximately
0.2Mb in the HG19 build. Results were conﬁrmed using the
SALSA MLPA P160 STS kit (MRC-Holland, the Netherlands),
which contains probes for each exon (1–10) of the STS gene,
as well as other control probes on the X chromosome. MLPA
data were analysed using the GeneMarker v1.91 software and
intra-sample normalisation was performed.
The QF-PCR result was consistent with disomy 13, 18 and 21
and a male (XY) fetus. The karyotype result was normal male, 46,
XY. The direct CVS microarray result indicated a 332kb loss for
the short arm of chromosome X with breakpoints within Xp22.31
[arr Xp22.31(7,223,740–7,555,450)×0] (log2 ratio: 1.52). This loss
disrupted the STS (steroid sulphatase, OMIM #300747) gene,
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indicating a deletion of exons 8, 9 and 10, as well as possible
deletion of exon 7 (Figure 1A). This deletion predicts a likely STS
deﬁciency syndrome (X-linked ichthyosis, OMIM #308100)
phenotype in a male fetus.6 Parental follow-up using microarray
indicated no evidence of copy number change in this region in
either parent, suggesting the de novo origin of this copy number
loss in the fetus (Figure 1A). In view of the likely pathogenic nature
of this deletion, the result was reported following discussion
with our clinical review panel. Given the small size of the loss
on chromosome X, there were no BAC (bacterial artiﬁcial
chromosome) clones available within the deleted region, and
therefore, conﬁrmatory FISH (ﬂuorescence in situ hybridization)
testing was not performed.
The pregnancy continued and at birth the neonate had
no sign of ichthyosis and subsequent microarray testing
on DNA from neonatal blood failed to conﬁrm the deletion
disrupting the STS locus. Stored DNA from CVS-CC was also
tested by microarray, and there was again no evidence of
the deletion (Figure 1A). All array results met internal
quality control standards.
Figure 1 (A) Array CGH results. Magniﬁcation of the STS gene and copy number loss on the X chromosome at Xp22.31. The deletion region is
highlighted in red. The STS gene is shown as a red block at the bottom left. Exons are shown as black lines within the STS gene box. A copy
number loss disrupting the STS gene is identiﬁed in the direct chorionic villus sample (CVS). This loss included exons 8, 9 and 10 of the STS
gene. Exon 7 is located adjacent to the call, but before the next normal probe, thus it could also be deleted. The results from DNA from CVS-CC
(CC), neonatal (Blood), maternal (Mother) and paternal (Father) blood samples indicate no evidence of this copy number loss. Therefore, the
deletion is de novo and conﬁned to the placenta. (B) Multiplex Ligation-dependent Probe Ampliﬁcation results for the STS locus. Only proband
direct CVS (CVS), CVS-CC (CC) and neonatal blood (Blood) are shown here and are compared with a normal male sample and a sample with
a known standard STS deletion. An intensity ratio between 0.8 and 1.2 corresponds to a normal copy number (i.e. 1 copy in males). Males
carrying the deletion will show no ampliﬁcation and an intensity ratio of 0 (0 copies). It is clear that exons 7–10 of the STS gene are deleted in
a mosaic state in the direct CVS sample
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The array results from the direct CVS, CVS-CC and neonatal
blood all share the same eight regions of copy number
variation, as well as two rare variants of unknown signiﬁcance,
both of which were maternally inherited, thereby eliminating
the possibility of a sample mix-up.
Because the detection of mosaicism by array CGH can be
problematic,7 we compared our results in this patient with
positive controls from our own laboratory database. Four
previous unrelated male probands with validated STS copy
number losses detected postnatally were examined and showed
an average log2 ratio of 2.5 (ranging from 2.25 to 2.8). The
log2 ratio of the atypical partial STS deletion in the direct CVS
presented in this report was 1.52, indicating that the copy
number loss was mosaic in the direct CVS preparation,
consistent with the admixture of two distinct cell lineage
populations. MLPA analysis of the direct CVS, CVS-CC, neonatal
blood and parental blood DNA, using the same direct approach,
conﬁrmed that the STS copy number loss seen by array CGHwas
not a technical artefact, involved exons 7–10 andwas conﬁned to
the placenta in a mosaic state (Figure 1B).
To our knowledge, this is the ﬁrst report of a potentially
clinically signiﬁcant copy number loss conﬁned to the placenta
and limited to the cytotrophoblast cell lineage detected by
array CGH and subsequently conﬁrmed by MLPA in a prenatal
setting. DNA extracted from direct CVS contains a mixture of
two cell populations derived from the cytotrophoblast and
mesenchymal core. Mesenchymal cells, that grow in culture
and are more likely to be representative of the fetal genotype,
are estimated to contribute up to 40–50% to the DNA extracted
from mid-trimester intermediate villi.8 Our microarray results
suggest that the microdeletion on chromosome X arose during
placentation and was conﬁned to the cytotrophoblast.
Microarrays have only recently been introduced into clinical
service for prenatal diagnosis, and so the frequency of discrepant
results obtained by analysis of uncultured CVS and other sources
of geneticmaterial are as yet unknown. Our report highlights the
possibility of CPM for submicroscopic rearrangements and
suggests that precautions should be taken to minimise this risk.
We would suggest that this case demonstrates the need for
DNA extraction from a larger portion of the whole villi to
maximise representation of the whole sample and to minimise
discrepant results. Previous experience suggests that particular
care is required to ensure that the mesenchymal core DNA
fraction is sufﬁciently well represented to avoid such results.9
Although this protocol was followed in the case reported here,
we still encountered discrepant results. Therefore, microarray
results obtained from DNA extracted from uncultured CVS in
the absence of clearly identiﬁed clinical ﬁndings (e.g. relevant
prenatal sonographic ﬁndings) should be interpreted with
caution. We suggest that, in the absence of such supporting
evidence, follow-up and conﬁrmation of potentially clinically
signiﬁcant copy number changes identiﬁed in DNA obtained
from uncultured CVS should be performed on CVS-CC or
amniotic ﬂuid prior to reporting. In cases where CPM is
suspected on microarray, FISH would be the preferred method
for conﬁrmation, as long as cultured cells and appropriate FISH
probes are available. In addition, given the selective growth of
the mesenchymal core cells in culture, the use of CVS-CC as
the preferred tissue for microarray testing would minimise the
incidence of CPM and false-positive ﬁndings. However, in a
clinical diagnostic service, the use of CVS-CC instead of CVS
would result in a delay in reporting of the urgent prenatal results.
Moreover, cultural artefacts may arise that would not represent
the true fetal genotype.10 The incidence of such artefacts would
increase with prolonged culturing. In diagnostic laboratories,
good practice would be to include in reports a standard rider
stating that CPM cannot be excluded.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Use of microarray for prenatal diagnosis increases the detection of
pathogenic chromosomal rearrangements.
• CPM is a well-established phenomenon occurring in 1–2% of CVS.
WHAT DOES THIS STUDY ADD?
• CPM can occur for submicroscopic copy number changes detected
by array CGH in DNA from uncultured CVS. In order to minimise the
risk of false-positive results in these cases, detected copy number
changes should be conﬁrmed in a different source of material, such
as cultured cells.
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